You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Claims for Patent: 9,164,098


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 9,164,098
Title:Determining an expression status of human epidermal growth factor receptor 2 (HER2) in a biological sample
Abstract: A method for determining an expression of human epidermal growth factor receptor 2 (HER2) of a subject. The method includes providing a sample from the subject; measuring one of (i) amounts of two or more proteins in the sample, each protein having a molecular weight substantially equal to 4740, 8404, 8419, 8435, 8450, 8455, 8465, 8570, 8607 or 8626 atomic mass units, and (ii) amounts of at least one of human cystein-rich intestinal protein 1 (CRIP1), one or more variants of the human cystein-rich intestinal protein 1 (CRIP1 variants), and proteolytic digestion products thereof in the sample; and comparing the amounts of the proteins to control amounts, which control amounts are determinative of the expression of the human epidermal growth factor receptor 2.
Inventor(s): Albers; Christian (Bremen, DE), Belau; Eckhard (Lilienthal, DE), Deininger; Soren-Oliver (Leipzig, DE), Rauser; Sandra (Munich, DE), Suckau; Detlev (Grasberg, DE), Walch; Axel (Baldham, DE)
Assignee: Bruker Daltonik GmbH (Bremen, DE)
Application Number:12/879,619
Patent Claims:1. A method for determining an expression of human epidermal growth factor receptor 2 (HER2) of a subject to determine an appropriate breast cancer treatment, comprising: providing a breast cancer sample from the subject; measuring amounts of two proteins by mass spectrometry, wherein the two proteins have a molecular weight of 8404 atomic mass units and 8419 atomic mass units, respectively, the molecular weights being assigned to the human cysteine-rich intestinal protein 1 (CRIP1) and a structurally modified variant human cysteine-rich intestinal protein 1, respectively; comparing the amounts of the proteins to control amounts; determining the expression of the human epidermal growth factor receptor 2 to be up-regulated if the amounts of the two proteins compared to the control amounts are increased; and predicting a beneficial effect to Trastuzumab when there is an up-regulated expression of the human epidermal growth factor receptor 2.

2. The method of claim 1, where the amount of at least one further protein is measured by mass spectrometry and compared to a control amount, the at least one protein having a molecular weight substantially equal to 8435, 8450 or 8465 atomic mass units is classified as being related to the one or more variants of the human cysteine-rich intestinal protein 1, wherein expression of the human epidermal growth factor receptor 2 is determined as up-regulated if the amount of the at least one further protein compared to the control amount is increased.

3. The method of claim 1, where the structurally modified variant comprises at least one of an in vivo or in vitro modification, a post-translational modification, a sequence variation, and a point mutation.

4. The method of claim 1, where the two proteins are measured and identified using tandem mass spectrometry.

5. The method of claim 1, where the human cysteine-rich intestinal protein 1 is modified by one or more structural variations, or modified by at least one mutation.

6. The method of claim 5, where the one or more structural variations comprise at least one of disulfide bond formation, one or more methyl groups, and oxygen atoms.

7. The method of claim 5, where at least one of modifications and mutations is located in a core region of the human cysteine-rich intestinal protein 1.

8. The method of claim 1, where the proteins are extracted from the sample, between the steps of providing the sample and measuring the amounts of proteins in the sample, utilizing an antibody or other affinity reagents.

9. The method of claim 8, where the antibody or other affinity reagents comprises aptamers or affibodies, which are specific for the human cysteine-rich intestinal protein 1 or its variants.

10. The method of claim 1, where the breast cancer sample of the subject is homogenized tissue or extracted tissue.

11. The method of claim 10, where the homogenized or extracted tissue comprises one of a lysate of a homogenized tissue, and a tissue section.

12. The method of claim 11, where the tissue section is analyzed using an imaging mass spectrometer.

13. The method of claim 12, where the imaging mass spectrometer comprises a matrix assisted laser desorption/ionization imaging mass spectrometer.

14. The method of claim 1, wherein the amount of at least one further protein is measured by mass spectrometry and compared to a control amount, the at least one further protein having a molecular weight substantially equal to 4740, 8455, 8570, 8607 or 8626 atomic mass units and being classified as being related to fragments of the human epidermal growth factor receptor 2.

15. A method for determining an expression of human epidermal growth factor receptor 2 (HER2) of a subject, comprising: providing a sample from the subject; measuring amounts of two proteins by mass spectrometry, wherein the two proteins have a molecular weight of 8404 atomic mass units and 8419 atomic mass units, respectively, the molecular weights being assigned to the human cysteine-rich intestinal protein 1 (CRIP1) and a structurally modified variant human cysteine-rich intestinal protein 1, respectively; comparing the amounts of the proteins to control amounts; and determining the expression of the human epidermal growth factor receptor 2 to be up-regulated if the amounts of the two proteins compared to the control amounts are increased.

16. The method of claim 15, where the amount of at least one further protein is measured by mass spectrometry and compared to a control amount, the at least one protein having a molecular weight substantially equal to 8435, 8450 or 8465 atomic mass units is classified as being related to variants of the human cysteine-rich intestinal protein 1, wherein the expression of the human epidermal growth factor receptor 2 is determined as up-regulated if the amount of the at least one further protein compared to the control amount is increased.

17. The method of claim 15, where the proteins are extracted from the sample, between the steps of providing the sample and measuring the amounts of proteins in the sample, utilizing an antibody or other affinity reagents.

18. The method of claim 15, where the sample of the subject comprises one of a body fluid, homogenized tissue and extracted tissue.

19. The method of claim 15, where the sample of the subject is a tissue section.

20. The method of claim 19, where the tissue section is analyzed using an imaging mass spectrometer.

21. The method of claim 15, where the amount of at least one further protein is measured by mass spectrometry and compared to a control amount, the at least one further protein having a molecular weight substantially equal to 4740, 8455, 8570, 8607 or 8626 atomic mass units and being classified as being related to fragments of the human epidermal growth factor receptor 2.

Details for Patent 9,164,098

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Genentech, Inc. HERCEPTIN trastuzumab For Injection 103792 09/25/1998 ⤷  Try a Trial 2029-09-10
Genentech, Inc. HERCEPTIN trastuzumab For Injection 103792 02/10/2017 ⤷  Try a Trial 2029-09-10
Genentech, Inc. HERCEPTIN HYLECTA trastuzumab and hyaluronidase-oysk Injection 761106 02/28/2019 ⤷  Try a Trial 2029-09-10
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.